According to Evoke Pharma, the company has received a notice of allowance from the US Patent and Trademark Office (USPTO) for patent application No. 17/366,829 (“Nasal Formulations of Metoclopramide”). The patent will cover the composition of Evoke’s Gimoti intranasal metoclopramide, which was approved by the FDA in June 2020 for the treatment of diabetic gastroparesis, with an expiration in 2029.
Earlier this year, the company announced that it had received a notice of allowance for patent No. 11628150, titled “Nasal Formulation of Metoclopramide,” which was published in April 2023 and which is set to expire in February 2030. Two other patents titled “Nasal Formulations of Metoclopramide” (Nos. 8,334,281 and 11,020,361) expire in 2029 and 2030. Patent No. 11,517,545, titled, “Treatment of Moderate and Severe Gastroparesis,” is scheduled to expire in 2038.
Evoke CEO David Gonyer commented, “This soon-to-issued patent further establishes our commercial and intellectual property footprint within the GI therapeutic space. We continue to hear stories of lives being changed with Gimoti and we believe our product can become the first-line treatment for those who suffer from the debilitating symptoms of diabetic gastroparesis. This disease continues to grow due to the increase in prevalence of diabetes and we are receiving significant market feedback regarding the implications of the new GLP-1 treatments which may uncover delayed gastric emptying. Diabetes and gastroparesis (delayed gastric emptying) remains our focus and Gimoti is the only non-oral outpatient treatment indicated to address the nausea, vomiting, abdominal pain and other symptoms brought on by this difficult disease.”
Read the Evoke Pharma press release.
